Comparación de la capacidad diagnóstica precoz de los biomarcadores de la enfermedad de Alzheimer en resonancia magnética cerebral y líquido cefalorraquídeo

Monge Argilés, JA; Blanco Cantó, MA; Leiva Salinas, C; Flors, L; Muñoz Ruiz, C; Sánchez Payá, J; Gasparini Berenguer, R; Leiva Santana, C.
Neurología (Barc., Ed. impr.) ; 29(7): 397-401, sept. 2014. tab
Artículo en Español | IBECS (España) | ID: ibc-127360

Documentos relacionados

  1. What Are the Reliable Plasma Biomarkers for Mild Cognitive Impairment? A Clinical 4D Proteomics Study and Validation.
  2. Accelerating Alzheimer's therapeutic development: The past and future of clinical trials.
  3. Computational Models for Biomarker Discovery.
  4. The performance of plasma phosphorylated tau231 in detecting Alzheimer's disease: A systematic review with meta-analysis.
  5. Fully automated measurement of plasma Aß42/40 and p-tau181: Analytical robustness and concordance with cerebrospinal fluid profile along the Alzheimer's disease continuum in two independent cohorts.
  6. Integrating Biomarkers From Virtual Reality and Magnetic Resonance Imaging for the Early Detection of Mild Cognitive Impairment Using a Multimodal Learning Approach: Validation Study.
  7. Diagnostic criteria in dementing illness. What's new?
  8. Alzheimer's Disease Plasma Biomarkers Distinguish Clinical Diagnostic Groups in Memory Clinic Patients.
  9. AD-BERT: Using pre-trained language model to predict the progression from mild cognitive impairment to Alzheimer's disease.
  10. Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline.